| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.22 | 3e-05 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | -0.2 | 0.0004 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | -0.19 | 0.0006 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.19 | 0.0005 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.18 | 0.001 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.17 | 3e-07 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.17 | 3e-07 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.17 | 0.002 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | -0.17 | 5e-06 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.17 | 1e-06 |